$VERU News

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Q3 EPS $(0.30) Beats $(0.32) Estimate

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Announces $21.8M Sales ATM Program With Oppenheimer, Canaccord

Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

Canaccord Genuity Maintains Buy on Veru, Maintains $25 Price Target

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Veru Inc. Q2 2026 Earnings Call Summary

Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...

Transcript: Veru Q2 2026 Earnings Conference Call

Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript